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ences on a scale running from 1 (perfect health) to 0 (all
worst or death depending on the interviewee’s decision).
The 8 single-attribute value functions were directly re-
vealed as well as the corner states values. Rating of par-
ticular multi-attribute health states was also done using
both VAS and SG. RESULTS: The limited number of
questionnaires excluded at the various different stages of
building the multiattribute utility function demonstrated
that such approaches are viable manners of gathering
original and high-quality information on the values and
judgements held by individuals in France with regard to
health. Secondly, analysis concluded that collected data
permit 1) to fit multi-attribute value and utility functions
for many individuals and 2) to discuss the appropriate-
ness of the multiplicative functional form. Results ob-
tained at the person-mean and person-median levels from
the French survey will be presented and discussed. Our
results confirm the interindividual variability of the pref-
erences already reported among Anglo-Saxon popula-
tions. As for most of the latter, these variations cannot be
explained by standard socio-demographic characteristics
such as the age, sex or socio-economic level of the inter-
viewees.
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OBJECTIVES: To develop a model for predicting thera-
peutic effectiveness from efficacy data. To estimate the
resource and health implications of sub-optimal drug use
in the general population. METHODS: A stochastic model-
ling approach was adopted to simulate drug effect ac-
cording to time. Non-compliance was simulated by prob-
ability functions describing the three main forms of drug-
taking behaviour: timing errors, missed doses and drug
holidays. Standard pharmacokinetic (PK) simulations for
multiple oral dosing based on these dosing profiles pro-
vided a basis for pharmacodynamic (PD) modelling in or-
der to evaluate the time course of drug effect. Iterations
were made for each PK-PD model with random compli-
ance profiles. RESULTS: Although the consequences of
non-compliance are varied, and mainly dependent upon
the disease being treated, some drugs are more forgiving
to non-compliance than others. That is, in the presence of
erratic dosing behaviour, therapeutic effect may be main-
tained. Forgiveness is an attribute which is dependent
both upon the properties of the drug and the pathophysi-
ology of the disease. The model demonstrates that drugs
which have a long duration of action in relation to their
dosing interval are the most forgiving, and this may be pre-
dicted on the basis of their PK-PD characteristics. CON-
CLUSIONS: Non-compliance is an important factor of
drug effectiveness. The forgiveness of a drug determines
the extent to which efficacy is affected by sub-optimal
drug use and has implications when considering cost-
effectiveness.
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In the last meeting of ISPOR, we presented a paper that
showed the actual cost-effectiveness of treatments in
practice can be reduced by the influence of statistical er-
rors such as type II () and type III (). OBJECTIVE:
Based on that research, this paper developed a further
theoretical framework for such estimation which pro-
vides a new method for power analysis of a clinical trial
and proper translation of its outcomes in terms of cost-
effectiveness. METHODS: Consider a statistical model of
a clinical trial for two regimens: a new treatment TA and
TB. Under the traditional two-sample binomial analysis,
we theoretically expanded it into power and sample sized
calculations with the cost-effectiveness ratios A and B,
respectively, for the regimens TA and TB. Furthermore, we
assume that the truth is TA is more cost-effective than TB.
Then, the binomial analyses were generalized under the
decision-analytic model that can reflect a reality in prac-
tice with three alternatives according to no error,  and 
errors possibly contained in the statistical conclusion of
the clinical trials for TA and TB. RESULTS: Two formu-
lae were developed mathematically to incorporate cost-
effectiveness; one is an expansion of the traditional
formula for sample-size calculation with the cost-effec-
tiveness ratios A and B, and the other a more realistic
one with A and B, and the modified cost-effectiveness
ratio adjusted by the statistical  and  errors using A
and B. CONCLUSIONS: The newly developed formulae
can offer a more theoretically sound description to design
a clinical trial beyond the traditional techniques.
PMDM2
GUIDING PRINCIPLES TO COMPARE THE 
EFFICACY OF NOVEL DRUGS USING RCT 
MATCHED ARM COMPARISONS
Läer C, LeLorier J
Centre de recherche, Hôtel-Dieu du Centre hospitalier de 
l’Université de Montréal, Montréal, QC, Canada
OBJECTIVE: Our goal was to develop a set of evidence-
based guiding principles for the comparison of two novel
drugs of the same therapeutic class when direct head-to-
head comparisons are lacking. The principles are in-
tended to guide researchers, decision-makers, and formu-
